Cell multiplication in the absence of integrin-derived adhesive signals (anchorage-independent growth) is the phenotypic hallmark of neoplastic transformation. Therefore, the frequently observed up-regulation of some integrins in tumors has been interpreted as an epiphenomenon and not as a causative factor of oncogenic conversion. B 4 integrin stimulates proliferation and survival of epithelial cells and is overexpressed in human carcinomas, often in concomitance with up-regulation of the Met tyrosine kinase receptor for hepatocyte growth factor. Met is not endowed with transforming ability but can exploit the B 4 cytoplasmic tail as a substrate/adaptor for amplification of mitogenic and antiapoptotic responses, independently of cell adhesion. Here, we show that overexpression of B 4 is sufficient to transform rodent fibroblasts, enhances anchorage-independent growth of breast carcinoma cells, and induces tumorigenesis in nude mice; conversely, RNA interference-mediated depletion abrogates the transformed phenotype of neoplastic cells. These autonomous oncogenic properties are dramatically exacerbated upon Met coexpression, suggesting that the integrin can instigate the latent tumorigenic potential of the kinase. A B 4 nonadhesive variant still cooperates with Met for cellular transformation, confirming the adhesion-independent function of B 4 in magnification of Met biological effects. Conversely, a B 4 signaling-incompetent mutant that cannot be efficiently tyrosine phosphorylated by Met and displays reduced ability to activate phosphatidylinositol 3-kinasedependent and Ras-dependent pathways aborts transformation. Our findings define B 4 as a signaling accomplice (a ''servo-oncogene'') of tyrosine kinase proto-oncogenes in primary carcinogenesis, evoke an unorthodox function for a prototypic adhesion molecule in the positive regulation of anchorage-independent growth, and suggest the use of B 4 as a target for anticancer therapy. (Cancer Res 2005; 65(23): 10674-9) 
Introduction
Regulated proliferation of normal cells obeys a bimodal control by integrins and tyrosine kinase receptors, which together prime mitogenic signals in response to cell adhesion and growth factors, respectively (1) . In contrast, deranged proliferation of transformed cells circumvents anchorage dependence and relies on constitutive activation of tyrosine kinase-based pathways (2) . This tenet has obscured a potential causal role for integrins in oncogenic conversion, despite their frequent up-regulation in tumors (3) . A number of anecdotic reports suggest that the h 4 subunit of the a 6 h 4 integrin complex might be etiologically involved in cancer onset. h 4 was originally identified as a tumor-associated antigen (4) , and h 4 neo or overexpression has been repeatedly documented in human premalignant lesions and incipient neoplasms (5) . Moreover, in accordance with the notion that anchorage independence is the major phenotypic hallmark of neoplastic transformation, the tumorassociated functions of h 4 may not require the integrin adhesive activity. In human carcinomas, the topographical localization of h 4 is not restricted to cell membrane domains that are in contact with adhesive ligands but undergoes pericellular redistribution. Similarly, in animal models of experimental skin carcinogenesis, aberrant expression of unligated h 4 in keratinocytes of the upper epidermal layers coincides with suprabasal expansion of the proliferating compartment and with development of squamous cell carcinomas (6) . Finally, in cancer cells, h 4 can act as an adhesion-independent signaling substrate for the hepatocyte growth factor (HGF) receptor Met and as a docking platform for additional recruitment of signal transducers, with consequent optimization of HGF-dependent mitogenic and antiapoptotic responses (7) . The functional collaboration between h 4 and Met is corroborated by the observation that in human carcinomas, the two molecules are concomitantly upregulated in the same tumor types (5, 8) .
The in vivo expression patterns of h 4 in human tumors and its ability to foster cell accretion and limit cell attrition even when cells are not attached to physiologic substrates prompted us to investigate whether expression of h 4 , alone and in combination with Met, can induce cellular transformation and enhance tumorigenicity.
Materials and Methods
Antibodies and vectors. We used the following antibodies: anti-human Met and anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA), anti-h 4 integrin (Chemicon, Temecula, CA), anti-phosphotyrosine (Upstate Biotechnology, Charlottesville, VA). The h 4 cyto-T construct was generated by PCR amplification of the BssHII-NotI fragment of a h 4 template already containing the Y1257F and Y1494F substitutions ( from L.M. Shaw). To create the h 4 siRNA expression vector, oligonucleotides used by Chung et al. (9) were annealed and ligated into pSUPER between the BglII and HindIII sites. BamHI-and XhoI-digested inserts were then subcloned into the pRLL5 lentiviral vector. The constructs encoding for wild-type Met, kinaseinactive Met, and h 4 Dextra have already been described (7).
(Invitrogen, Carlsbad, CA)-mediated transfection, ( for NIH3T3), or with retroviral or lentiviral infection ( for ZR75, T47D, MDA-MB-231, and MEFs Statistics. Results are means F SEs. Comparisons were made using the two-tailed Student's t test. Ps < 0.05 were considered statistically significant.
Results and Discussion
Oncogenic properties of B 4 integrin in vitro . Rodent fibroblasts represent prototypic recipients for analysis of the transforming properties of candidate oncogene products and have the advantage of expressing negligible levels of endogenous h 4 and Met (Fig. 1A ). NIH3T3 cells with ectopic expression of h 4 were able to form foci on plastic and colonies in soft agar (P < 0.01; Fig Similar results were obtained upon h 4 and/or Met expression in MEFs (Fig. 1D) ; again, single Met transfection was not accompanied by visible transformation (Fig. 1E) ; transfection of h 4 alone resulted in the development of a limited but clearly detectable number of sizeable foci, and cotransfection of Met and h 4 gave rise to a significant amount of foci with considerable dimensions (P < 0.01; Fig. 1E ; Supplementary Table 3) . Together, these results indicate that h 4 is able to induce cell transformation in vitro, and that this ability is exploited to unleash the silent transforming potential of the Met proto-oncogene.
Integrity of B 4 -dependent signals but not of B 4 extracellular portion is required for B 4 -mediated transformation. The h 4 Figure 1 . Autonomous and Met-dependent oncogenic properties of h 4 integrin in vitro . A, expression of h 4 and Met in NIH3T3 total cell lysates. Cells were transfected with the indicated constructs. In the case of single protein expression, cells were cotransfected with an empty vector. B, focus-forming assay in NIH3T3. Columns, means of two independent experiments done in quadruplicate; bars, SE. C, soft agar assay in NIH3T3. Columns, means of two independent experiments done in quadruplicate; bars, SE. D, expression of Met and h 4 in MEF total cell lysates. Cells were infected with the indicated vectors (plus empty vector when a single protein was expressed). E, focus-forming assay in MEFs. Columns, means of two independent experiments done in quadruplicate; bars, SE. cytoplasmic tail can be tyrosine phosphorylated by Met, which is important for amplification of Met-dependent proliferation and survival (7) . To verify whether this substrate/adaptor function of the integrin is also involved in Met oncogenic activity, we decided to test the transforming ability of a mutant of h 4 with reduced substrate capacity for Met. To generate this mutant, we did a progressive phenylalanine mutagenesis of some critical tyrosines located in the h 4 intracellular domain and evaluated the Metdependent tyrosine phosphorylation status of the integrin.
Coexpression of Met and h 4 in COS cells resulted in elevated tyrosine phosphorylation of h 4 ( Fig. 2A) , whereas expression of h 4 and a kinase-inactive Met isoform (Met KÀ ) did not produce significant tyrosine phosphorylation of the integrin, confirming our previous observation that h 4 is an optimal substrate for Met kinase activity ( Fig. 2A; Dextra produced a number of foci superimposable to that of cells expressing Met and wild-type h 4 (P = 0.7; Fig. 2B ; Supplementary Table 1) . Together, these results indicate that abolition of the cytoplasmic signaling activity of h 4 curtails its transforming properties, whereas suppression of the integrin adhesive function leaves them intact.
Oncogenic properties of B 4 integrin in vivo. We extended the data obtained in the in vitro transformation assays to tumorigenesis in vivo by implanting s.c. xenografts of NIH3T3 cells in immunocompromised mice. In the first 3 weeks after injection, cells expressing h 4 alone or Met and h 4 gave rise to actively expanding tumors, although growth of lesions produced by fibroblasts expressing only h 4 was more indolent (P < 0.01; Fig. 2C; Supplementary Tables 4-7 ), in accordance with the in vitro results. Again, mice injected with cells expressing Met and h 4 cyto-T did not manifest s.c. masses, whereas the group injected with cells expressing Met and h 4 Dextra developed visible tumors (Fig. 2C) . In this latter cohort, xenografts grew with slower kinetics compared with cells expressing Met and wild-type h 4 , suggesting that the matrix-binding activity of the integrin may provide an additional oncogenic stimulus in vivo.
Prolonged mice monitoring showed that almost all animals, including controls injected with vector cells, started developing tumors after 3 weeks, confirming the observation that NIH3T3 cells are occasionally prone to spontaneous tumorigenesis (Table 1) . We Phe) phenylalanine substitutions of critical signaling tyrosines. B, focus-forming assay in NIH3T3 expressing the indicated cDNAs. Columns, means of two independent experiments done in quadruplicate; bars, SE. C, growth curves of NIH3T3 xenografts in nude mice, monitored during the first 3 weeks after injection (n = 6 for each experimental group). Green, Met/wild-type h 4 ; red, Met/h 4 Dextra ; blue, h 4 alone. thus decided to perform a similar experiment employing MEFs, which proved to be less vulnerable to oncogenic conversion in preliminary experiments. In this setting, only cells expressing Met and h 4 were able to form tumors, whereas all other transfectants (Met alone, h 4 alone, and Met/h 4 cyto-T ) were nontumorigenic even over an extended period of time (120 days; Table 1 ). Hence, h 4 displays significant albeit not dramatic oncogenic properties in vivo, which are magnified in the presence of Met.
Oncogenic properties of B 4 in human epithelial cells. To further validate a causal role for h 4 in tumorigenesis in a setting that is more relevant for human cancer, we expanded the panel of cell types tested to include human epithelial cells. As cellular models for this analysis, we chose various cell lines derived from the mammary epithelium, in which progression towards the neoplastic phenotype is accompanied by up-regulation of both h 4 (13) and Met (14) .
In MDA-MB-231 breast carcinoma cells, which physiologically express both molecules, we either enhanced integrin levels by infection with a h 4 -encoding retrovirus, or abated them by lentiviral delivery of small interfering RNAs (siRNA; Fig. 3A) . When subjected to a soft agar assay, mock cells infected with a control (scrambled) siRNA were able to form nonadherent colonies at high efficiency. Strikingly, integrin overexpression strongly increased the colony-forming ability of these cells (not only in absolute numbers but especially in size; P = 0.01; Supplementary Table 8) , whereas h 4 knockdown resulted in almost complete abolition of anchorageindependent growth (P < 0.01; Fig. 3B ).
In MCF-10A and B5-589 cells, derived from the normal mammary epithelium, overexpression of h 4 , Met, or both was not sufficient to induce a transformed phenotype (data not shown), confirming the established notion that normal human epithelial cells are more difficult to transform than rodent fibroblasts. We thus analyzed ZR75 and T47D mammary carcinoma cells, which do not express h 4 and Met and, despite being of tumor origin, do not display an overt transformed phenotype: indeed, both lines are well differentiated, synthesize high amounts of E-cadherin, grow poorly in soft agar, and are not tumorigenic in nude mice unless an external estrogen supply is provided. In these cells, expression of h 4 substantially enhanced the number of colonies (P < 0.01; Fig. 3C-F) , which was further increased upon coexpression of Met (P < 0.01; Fig. 3C-F Tables 9 and 10 ), but they formed less colonies compared with cells expressing Met and wild-type h 4 ( Fig. 3C-F) . This could be due to the fact that h 4 Dextra , although competent for transduction of Met-dependent signals, is unable to convey adhesive and survival signals provided by laminins endogenously produced by epithelial cells (15) . In line with that observed in fibroblasts, coexpression of Met and the h 4 cyto-T -signaling dead mutant did not significantly affect basal anchorage-independent growth in both cell lines (Fig. 3C-F) .
Finally, consistent with the transformed phenotype displayed in vitro, ZR75 cells expressing only h 4 exhibited increased tumorigenic potential in nude mice compared with mock cells, in the absence of any exogenous estradiol treatment (P < 0.05; Fig. 3G ; Supplementary Table 11) . Cells expressing Met and h 4 developed tumors with faster kinetics, whereas cells expressing Met and h 4
Dextra grew more rapidly than cells expressing Met alone (P < 0.05; Fig. 3G ; Supplementary Table 11) but slower than cells expressing Met and wild-type h 4 . In contrast, the growth curves of cells expressing Met and h 4 cyto-T were superimposable to those of mock and Met-expressing cells (P = 0.72; Fig. 3G ).
Conclusions
Our data show that h 4 integrin is endowed with transforming ability and conspires with the tyrosine kinase Met for patent tumorigenesis functioning as a Met substrate. This activity, which significantly induces oncogenic conversion of rodent fibroblasts, is not sufficient for de novo transformation of human normal epithelial cells but is necessary to maintain the tumorigenic phenotype of carcinoma cells and strongly exacerbates their cancerous properties.
A number of phenomenological studies substantiate the observed collaboration between h 4 and Met in cancer formation. Although both molecules are expressed in a limited subset of normal adult tissues, they seem concomitantly overrepresented and similarly localized in a variety of human malignancies, including skin, thyroid, breast, pancreas, lung, nasopharyngeal, and bladder carcinomas (5, 8, 16) . In this respect, analysis of the promoter regions of h 4 (17) and Met (18) reveals that both sequences share response elements for the same nuclear factors, implying common regulatory mechanisms for their transcriptional induction. Together with protein coexpression, the cooperation between h 4 and Met in oncogenic conversion might also have a genetic basis. Several germ line and somatic mutations of the Met gene have been found in human renal papillary carcinomas (19) , but most them do not confer transforming ability to Met either in fibroblasts (10) or epithelial cell lines (20) . Intriguingly, all these tumors bearing Met mutations display trisomy of chromosome 17, where the h 4 genomic locus resides (21) . This suggests a potential gene-dosage effect, whereby enhanced production of h 4 could awake the dormant oncogenic activity of Met.
In conclusion, our findings disclose an unanticipated role for h 4 as a servo-oncogene of tyrosine kinase proto-oncogenes, which elevates this integrin from candidate status to culprit status in tumor development. Implicit in these findings is the issue that targeting the signaling function of h 4 in neoplastic contexts could add therapeutic value to experimental approaches aimed at interfering with cancer growth and progression.
